Immunovaccine raises $11.2 million, gets TSX listing

Guest Contributor
November 12, 2014

Immunovaccine Inc is moving up from the TSX Venture Exchange to the Toronto Stock Exchange following a successful initial public offering (IPO) and private placement in September. The IPO and private placement raised $9.5 million and $1.7 million respectively for a total of $11.2 million. Immunovaccine will use the proceeds for additional R&D and clinical advancement of its cancer and infectious diseases candidates. The Halifax-based company's lead cancer vaccine is moving into multiple Phase II clinical trials and it is developing potential vaccines for the Ebola virus, anthrax and respiratory syncytial virus....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.